Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 314

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 314
---
 to determine the remuneration package of executive directors and senior management of the group and during the year to consider grants of share options and LTIP awards and other remuneration related matters. Remuneration matters are also considered and approved by way of written resolutions and where warranted, at additional meetings. The Remuneration Committee held four meetings in 2024 with 100% attendance.

The responsibilities of the Remuneration Committee are to assist the Board in achieving its objectives of attracting, retaining and motivating a broader and more diverse pool of employees of the highest caliber and experience needed to shape and execute the strategy across the group’ s substantial, diverse and international business operations. It assists the group in the administration of a fair and transparent procedure for setting remuneration policies for all directors and senior management of the group. Whilst the Board retains its power to determine the remuneration of non-executive directors, the responsibility for reviewing and determining the remuneration package of individual executive directors and senior management of the group is delegated to the Remuneration Committee. The Committee is authorized to obtain, at the company’ s expense, external legal or other professional advice on any matters within its Terms of Reference.

Table of Contents

2024 Goals

In 2024, this strategy delivered significant results to our operations. As described below, a considerable number of company goals were set and achieved in 2024 on our regulatory, clinical development, discovery research, manufacturing, commercial, financial, business development, organizational and sustainability operations. These included:

Regulatory goals. Filed regulatory submissions in China of sovleplenib for immune thrombocytopenia, of savolitinib in MET exon 14 skipping alteration lung cancer including for treatment-naïve patients, of savolitinib with Tagrisso for EGFR TKI refractory lung cancer, of fruquintinib with sintilimab for EMC, and of tazemetostat for FL; obtained approval of fruquintinib with sintilimab for EMC in China, and of fruquintinib for CRC in the European Union and Japan. Also obtained fruquintinib approvals for CRC in Argentina, Australia, Canada, Hong Kong, Israel, Singapore, Switzerland, the United Arab Emirates, South Korea and the United Kingdom.

Clinical goals. Completed portfolio prioritization; enrolled first patients in the registration trials of ranosidenib for leukemia, sovleplenib for anemia, as well as the first patients enrolled